RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Soochow University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07609446, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Current or prior other malignancy, unless curative treatment has been performed and there has been no evidence of recurrence or metastasis within the past 5 years;

    Exclusion criterion 1

  3. ECOG-PS score 0-2;

    Inclusion criterion 7

  4. Hepatic function: serum bilirubin ≤2.0 × ULN; serum ALT and AST ≤2.5 × ULN;

    Inclusion criterion 10

    Renal function: creatinine clearance >30 mL/min;

    Inclusion criterion 11

    Hepatic or renal dysfunction unrelated to lymphoma: alanine aminotransferase (ALT) >3 times the upper limit of normal, aspartate aminotransferase (AST) >3 times the upper limit of normal, total bilirubin (TBIL) >2 times the upper limit of normal, or serum creatinine >1.5 times the upper limit of normal;

    Exclusion criterion 3

  5. Pregnant or lactating women, or women of childbearing potential who have not used contraceptive measures;

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07609446, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 18 years, regardless of sex;
  • Confirmed diagnosis of follicular lymphoma (FL), or histopathologically confirmed CD20-positive marginal zone lymphoma (MZL), including extranodal marginal zone lymphoma (MALT), splenic marginal zone lymphoma (SMZL), and nodal marginal zone lymphoma (NMZL),or confirmed diagnosis of indolent mantle cell lymphoma (MCL);
  • Patients with a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL);
  • Confirmed diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia;
  • Presence of indications for treatment of indolent B-cell lymphoma;
  • No prior systemic antitumor therapy for lymphoma;
  • ECOG-PS score 0-2;
  • Essentially normal bone marrow hematopoietic function, with routine blood tests as follows: white blood cell count >3000/uL, absolute neutrophil count ≥1.5 × 10\^9/L (use of granulocyte colony-stimulating factor is allowed), platelet count ≥75 × 10\^9/L (transfusion to reach this minimum platelet count is allowed), and hemoglobin ≥9.0 g/dL (prior red blood cell transfusion or use of recombinant human erythropoietin is allowed). If peripheral blood abnormalities are caused by lymphoma involvement of the bone marrow or spleen, neutrophils≥1.0 × 10\^9/L and platelets≥50 × 10\^9/L are acceptable (the investigator may determine at his/her discretion whether enrollment is appropriate);
  • Normal function of major organs:
  • Hepatic function: serum bilirubin ≤2.0 × ULN; serum ALT and AST ≤2.5 × ULN;
  • Renal function: creatinine clearance >30 mL/min;
  • Expected survival≥3 months as judged by the investigator; Voluntary written informed consent signed before trial screening;

Exclusion Criteria:

  • Current or prior other malignancy, unless curative treatment has been performed and there has been no evidence of recurrence or metastasis within the past 5 years;
  • Lymphoma involvement of the central nervous system or transformation to a higher-grade lymphoma;
  • Hepatic or renal dysfunction unrelated to lymphoma: alanine aminotransferase (ALT) >3 times the upper limit of normal, aspartate aminotransferase (AST) >3 times the upper limit of normal, total bilirubin (TBIL) >2 times the upper limit of normal, or serum creatinine >1.5 times the upper limit of normal;
  • Other serious medical conditions that would affect this study (e.g., uncontrolled diabetes, gastric ulcer, or other serious cardiopulmonary diseases). The investigator has the authority to make this determination;
  • Severe or uncontrolled infection;
  • Clinically manifest central nervous system dysfunction;
  • Major surgery within the past 30 days (excluding lymph node biopsy);
  • Pregnant or lactating women, or women of childbearing potential who have not used contraceptive measures;
  • Allergy to the study drug; Patients considered unsuitable for enrollment by the investigator.

Quoted from ClinicalTrials.gov, NCT07609446, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07609446, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07609446